Modified BCG vaccine strengthens protection against TB
· Medical Xpressedited by Sadie Harley, reviewed by Andrew Zinin
Sadie Harley
Scientific Editor
Meet our editorial team
Behind our editorial process
Andrew Zinin
Chief Editor
Meet our editorial team
Behind our editorial process Editors' notes
This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
fact-checked
peer-reviewed publication
trusted source
proofread
The GIST Add as preferred source
Researchers from the Centenary Institute and the University of Sydney have developed a modified version of the tuberculosis (TB) vaccine BCG that provided stronger and more sustained protection against TB. In preclinical tests in mice, the modified vaccine showed potential as a new approach to improving the effectiveness of TB vaccination.
A bacterial infection caused by Mycobacterium tuberculosis, TB remains a major global health challenge, responsible for around 1.2 million deaths each year.
BCG is currently the only available vaccine against TB, but its effectiveness varies. It provides protection against severe forms of TB in infants and young children but offers only limited protection for adults.
The study, published in Vaccine, found that modifying BCG to better target key immune cells improved the immune response generated by vaccination and provided longer-lasting protection against TB.
The researchers focused on dendritic cells, specialized immune cells that help the body recognize potential threats and activate other immune cells. They also play an important role in activating T cells, which help the body fight infections by coordinating the immune response.
In their research, the team genetically modified BCG to produce an antibody fragment that binds to DEC-205, a receptor found on the surface of dendritic cells, improving the interaction between BCG and these important immune cells.
"Our experiments showed that the modified BCG was taken up more effectively by dendritic cells and stimulated greater immune activity, including a stronger response from T cells, with more T cells producing multiple immune signaling molecules," said lead study author Dr. Claudio Counoupas from the Centenary Institute's Center for Infection and Immunity.
"Importantly, this enhanced immune response was associated with stronger protection against TB in the lungs, which was maintained for longer than the protection provided by standard BCG in our experimental model."
The researchers say the findings provide a strong basis for further investigation into ways of improving BCG and developing more effective TB vaccines.
"BCG has been used for more than 100 years, but there remains a need for new vaccines that can provide stronger and more sustained protection against TB," said senior study author Jamie Triccas from the University of Sydney.
"Our findings show that targeting BCG to dendritic cells can improve its protective efficacy in this preclinical model. While these findings are encouraging, we need to better understand whether this approach could ultimately translate into improved protection against TB in people."
The researchers continue to optimize the modified BCG vaccine.
Publication details
Claudio Counoupas et al, Targeted delivery of the BCG vaccine to dendritic cells improves protective efficacy against Mycobacterium tuberculosis, Vaccine (2026). DOI: 10.1016/j.vaccine.2026.128753
Journal information: Vaccine
Key medical concepts
Clinical categories
Infectious diseasesCommon illnesses & PreventionAllergy and immunology Provided by Centenary Institute Who's behind this story?
Sadie Harley
BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →
Andrew Zinin
Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →
Citation: Modified BCG vaccine strengthens protection against TB (2026, September 15) retrieved 15 September 2026 from https://medicalxpress.com/news/2026-09-bcg-vaccine-tb.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.